title: Short- and long-term outcomes of the titanium-NO stent registry.
abstract: BACKGROUND
  Five to 15% of the population have allergy to nickel, chromium, or molybdenum, which is a potential cause for in-stent restenosis. The Titan stent is made of stainless steel and is coated with titanium-nitride oxide (TiNOX), which completely prevents the discharge of metal elements. We performed a real-life multicenter registry to assess the short- and long-term characteristics of the Titan stent.
  
  
  RESULTS
  A total of 103 Titan stents was implanted in 100 patients. Patients were 61.4+/-12.6 years old (81 men). Risk factors included hypercholesterolemia (63%), hypertension (53%), diabetes mellitus (DM; 35%), and current smoking (23%). Indications for PCI (percutaneous coronary intervention) were acute coronary syndromes (ACS) in 68% [acute ST elevation myocardial infarction (MI) in 8%], stable AP (angina pectoris) in 25%, and silent ischemia in 7% of the patients. Fifty-two percent of the treated lesions were of Type B2 or C. Lesion length was 14.3+/-2.9 mm and stent diameter was 3.06+/-0.36 mm. Indications for stenting were prevention of restenosis in 66%, residual stenosis in 33%, dissection in 13%, acute MI in 13%, and in-stent restenosis in 7% of the patients. Procedural success was 100%, with no complications. At 30 days, there were no major adverse cardiac events (MACE), including death, MI, and revascularization. At 180 days, only three patients had TVR (target vessel revascularization); two had TLR (target lesion revascularization) (one PCI and one CABG [coronary artery bypass grafting]), and one patient had a new narrowing proximal to the stent and underwent CABG due to multivessel disease.
  
  
  CONCLUSIONS
  The Titan stent has a remarkable safety profile in high-risk patients and complex coronary lesions and excellent short- and long-term outcome with a very low clinical TLR rate.
authors.affiliation: Hadassah Hebrew University Medical Center, Jerusalem, Israel. mosseri@cc.huji.ac.il
authors.forename: Morris
authors.initials: M
authors.lastname: Mosseri
authors.forename: Israel
authors.initials: I
authors.lastname: Tamari
authors.forename: Michael
authors.initials: M
authors.lastname: Plich
authors.forename: Yonathan
authors.initials: Y
authors.lastname: Hasin
authors.forename: Mark
authors.initials: M
authors.lastname: Brizines
authors.forename: Aaron
authors.initials: A
authors.lastname: Frimerman
authors.forename: Hilton
authors.initials: H
authors.lastname: Miller
authors.forename: Jamal
authors.initials: J
authors.lastname: Jafari
authors.forename: Victor
authors.initials: V
authors.lastname: Guetta
authors.forename: Mivi
authors.initials: M
authors.lastname: Solomon
authors.forename: Chaim
authors.initials: C
authors.lastname: Lotan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects; D020099:Coated Materials, Biocompatible / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D007557:Israel; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011183:Postoperative Complications / Q000517:prevention & control; D012042:Registries / Q000706:statistics & numerical data*; D012307:Risk Factors; D013193:Stainless Steel; D015607:Stents / Q000009:adverse effects / Q000706:statistics & numerical data*; D013997:Time Factors; D014025:Titanium / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; C434243:titanium-nitride-oxide; D013193:Stainless Steel; D014025:Titanium